Releases
IMRA
--
0.00%
--
  • All
  • Financials
  • Insiders
More
Webull provides the latest Imara Inc (IMRA) stock and general news. This information may help you make smarter investment decisions.
About IMRA
Imara, Inc. is a clinical-stage biopharmaceutical company. The Company is developing and commercializing therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin. The Company’s product pipeline include IMR-687, which is an oral, once-a-day, potentially disease-modifying treatment for sickle cell disease (SCD), and beta-thalassemia. Its IMR-687 is a selective, small molecule inhibitor of phosphodiesterase-9 (PDE9). The Company is conducting a Phase 2a clinical trial of IMR-687 in adult patients with SCD and a Phase 2b clinical trial for the treatment of patients with beta-thalassemia.